The results from my summer project are included in this publication: Lee, M.S., Huang, T.F., Toro-Ramos, T., Fraga, M., Last, R.L
Patients in the phase 3b clinical trial maintained about 75-80% of their weight loss and health benefits, such as reduced waist circumference and improvements in blood pressure, blood sugar, triglycerides and cholesterol levels
HM12525A has been variously re-designated as JNJ-64565111 and now efinopegdutide, and this drug has been taken forward into Phase 2 trials (see below)
Lastly, a challenge in the field stemming from the clinically silent nature of PanINs and PanIN progression is the absence of a surrogate marker for pre-malignant progression
For example, if better sleep, improved recovery, or favorable body composition changes were partly related to increased growth hormone production, those benefits may become less noticeable after therapy ends